Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

This study has been terminated.
Information provided by:
Enzon Pharmaceuticals, Inc. Identifier:
First received: August 24, 2001
Last updated: June 23, 2005
Last verified: March 2004

Studies of PEG-paclitaxel have been terminated

Condition Intervention Phase
Neoplasm Metastasis
Drug: PEG-paclitaxel
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Resource links provided by NLM:

Further study details as provided by Enzon Pharmaceuticals, Inc.:

Study Start Date: May 2001
Estimated Study Completion Date: May 2002

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

None - Study has been terminated.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided Identifier: NCT00023166     History of Changes
Other Study ID Numbers: PTX-5001
Study First Received: August 24, 2001
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Enzon Pharmaceuticals, Inc.:
Phase I
Open label
Advanced primary and/or metastatic solid tumors
Neoplasm metastasis

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on March 26, 2015